Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900335984> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W2900335984 endingPage "S22" @default.
- W2900335984 startingPage "S21" @default.
- W2900335984 abstract "Lung cancer is the fifth most commonly diagnosed cancer but the leading cause of cancer deaths in Australia. Lung cancer has five-year survival rate of only 16%, partly due to diagnosis at an advanced stage. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounting for over 80% of all cases. Recently, treatment strategies for NSCLC are moving from chemotherapy-based regimens to targeted therapies. Many of these therapies have been assessed for public subsidy via the Pharmaceutical Benefits Scheme (PBS) in Australia. The objective of this study was to explore the main features that contribute to successful reimbursement for NSCLC therapies in the last 10 years in Australia. Pharmaceutical Benefit Advisory Committee (PBAC) recommend new medicines for listing on the PBS and disseminate their advice to the public using Public Summary Documents (PSD). A search of PSDs from 2008 to 2018 for medicines with specified indication of NSCLC was performed. Key issues raised in the PSDs were reviewed. From 2008 onwards, 49 submissions for 13 medicines (mean: 2.5 submissions; range: 1-5) for treatment of NSCLC have been assessed by the PBAC. The therapies were mainly targeted tyrosine kinase inhibitors (TKI) or immunotherapies, which are altering the clinical algorithm in NSCLC (to be presented in accepted poster). Seven medicines were recommended by the PBAC in this period, all treating locally advanced or metastatic NSCLC. Successful submissions either presented a cost-minimisation analysis or treated a sub-group of patients with high clinical need. Other submissions reported a clinical benefit over existing therapies but were often rejected on cost-effectiveness grounds. Seven new medicines (7/13) for advanced NSCLC have been recommended for public subsidy in Australia since 2008 and have changed the clinical algorithm in NSCLC treatment. However, cost-effectiveness remains the biggest barrier to access." @default.
- W2900335984 created "2018-11-16" @default.
- W2900335984 creator A5049541840 @default.
- W2900335984 creator A5080355382 @default.
- W2900335984 date "2018-09-01" @default.
- W2900335984 modified "2023-09-30" @default.
- W2900335984 title "The Barriers to Reimbursement Success for Non-Small Cell Lung Cancer Therapies in Australia" @default.
- W2900335984 doi "https://doi.org/10.1016/j.jval.2018.07.166" @default.
- W2900335984 hasPublicationYear "2018" @default.
- W2900335984 type Work @default.
- W2900335984 sameAs 2900335984 @default.
- W2900335984 citedByCount "0" @default.
- W2900335984 crossrefType "journal-article" @default.
- W2900335984 hasAuthorship W2900335984A5049541840 @default.
- W2900335984 hasAuthorship W2900335984A5080355382 @default.
- W2900335984 hasBestOaLocation W29003359841 @default.
- W2900335984 hasConcept C126322002 @default.
- W2900335984 hasConcept C143998085 @default.
- W2900335984 hasConcept C160735492 @default.
- W2900335984 hasConcept C162324750 @default.
- W2900335984 hasConcept C2426938 @default.
- W2900335984 hasConcept C2776256026 @default.
- W2900335984 hasConcept C2778793514 @default.
- W2900335984 hasConcept C2779703844 @default.
- W2900335984 hasConcept C50522688 @default.
- W2900335984 hasConcept C512399662 @default.
- W2900335984 hasConcept C71924100 @default.
- W2900335984 hasConcept C98274493 @default.
- W2900335984 hasConceptScore W2900335984C126322002 @default.
- W2900335984 hasConceptScore W2900335984C143998085 @default.
- W2900335984 hasConceptScore W2900335984C160735492 @default.
- W2900335984 hasConceptScore W2900335984C162324750 @default.
- W2900335984 hasConceptScore W2900335984C2426938 @default.
- W2900335984 hasConceptScore W2900335984C2776256026 @default.
- W2900335984 hasConceptScore W2900335984C2778793514 @default.
- W2900335984 hasConceptScore W2900335984C2779703844 @default.
- W2900335984 hasConceptScore W2900335984C50522688 @default.
- W2900335984 hasConceptScore W2900335984C512399662 @default.
- W2900335984 hasConceptScore W2900335984C71924100 @default.
- W2900335984 hasConceptScore W2900335984C98274493 @default.
- W2900335984 hasLocation W29003359841 @default.
- W2900335984 hasOpenAccess W2900335984 @default.
- W2900335984 hasPrimaryLocation W29003359841 @default.
- W2900335984 hasRelatedWork W1967103478 @default.
- W2900335984 hasRelatedWork W2013475220 @default.
- W2900335984 hasRelatedWork W2032912323 @default.
- W2900335984 hasRelatedWork W2169616599 @default.
- W2900335984 hasRelatedWork W2372561159 @default.
- W2900335984 hasRelatedWork W2375344515 @default.
- W2900335984 hasRelatedWork W2387455091 @default.
- W2900335984 hasRelatedWork W2390152934 @default.
- W2900335984 hasRelatedWork W3093065934 @default.
- W2900335984 hasRelatedWork W3211482644 @default.
- W2900335984 hasVolume "21" @default.
- W2900335984 isParatext "false" @default.
- W2900335984 isRetracted "false" @default.
- W2900335984 magId "2900335984" @default.
- W2900335984 workType "article" @default.